ETF-Investor

UTHR United Therapeutics

$559.10-3.16%2026-11-19 · Quote reference; see timestamp

01Recent performance

PeriodReturnHistorical percentile
Daily-3.16%Insufficient history
WTD—Insufficient history
MTD—Insufficient history
Period comparison through 2026-11-19
YTD—
From 52W high—
IV30—

Loading full research…

02How expensive is the company?

TTM PE 21.11×

TTM PE 21.11× · 70.97%
0%25%50%75%100%

Actual history 19.97Y · 217 month-end samples · 2006-11-30 — 2026-10-30

A comparison with its own history, not a standalone investment decision.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
2004-11-302026-10-30

PB 3.79×

PB 3.79× · 71.25%
0%25%50%75%100%

Actual history 19.97Y · 240 month-end samples · 2006-11-30 — 2026-10-30

PB is affected by buybacks and equity structure; it is not a standalone trade signal.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
1999-08-312026-10-30

03Earnings outlook

Forward PE20.38×
Expected EPS growth—

Forward PE · Futu · 2026-11-01

No verified comparable EPS growth forecast. Growth is not inferred from valuation ratios.

No verified comparable Forward PE history; no percentile scale is shown.

04ETFs holding the company

Loading full research…

05Peers & similar companies

Peers and similar companies first, followed by common stocks where needed.

Watch
ABBV——Similar business————————
AMGN——Similar business————————
BIIB——Similar business————————
GILD——Similar business————————
JNJ——Similar business————————
LLY——Similar business————————
MRK——Similar business————————
PFE——Similar business————————
REGN——Similar business————————
VRTX——Similar business————————

Loading existing stock data…

Percentiles use each company’s own history; actual years appear beside values. Missing data is shown as —. Quote and valuation dates may differ; hover over values for available dates.

06Understand the company

The business in one sentence
Develops and sells treatments including cardiopulmonary therapies.

How it earns money
Sells pulmonary hypertension therapies, with products such as Tyvaso offered in different delivery formats.

Why customers choose it · Research perspective
Convenience, prescribing experience and coverage influence use. New indications need separate evidence.

What to watch next · Research perspective
Track Tyvaso prescriptions and sales, other products and trial readouts to separate operations from pipeline upside.

Sources

United Therapeutics · Company filing

Futu · United Therapeutics company profile

Sources checked

For research, not personal investment advice.

PASSWORD-FREE ACCESS

Continue with email

We’ll send you a secure sign-in link. No password required.

By continuing, you agree to the Terms and acknowledge the Privacy Policy.